Drug Profile


Alternative Names: H-1PV; ParvOryx; parvovirus H1

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator German Cancer Research Center; University of Heidelberg
  • Developer Oryx GmbH & Co; University of Heidelberg
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Glioblastoma

Most Recent Events

  • 16 May 2018 Oryx GmbH completes a phase II trial in Pancreatic cancer (Metastatic disease, Inoperable/Unresectable) in Germany (Intratumoural and IV) (EudraCT2015-001119-11)
  • 16 May 2018 Efficacy data from a compassionate use programme in recurrent Glioblastoma presented at the 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT 2018)
  • 06 Nov 2017 Safety, efficacy and pharmacokinetics data from a phase I/II trial in Glioblastoma released by ORYX
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top